Tag Archives: york

#438886 This Week’s Awesome Tech Stories From ...

ARTIFICIAL INTELLIGENCE
This Chip for AI Works Using Light, Not Electrons
Will Knight | Wired
“As demand for artificial intelligence grows, so does hunger for the computer power needed to keep AI running. Lightmatter, a startup born at MIT, is betting that AI’s voracious hunger will spawn demand for a fundamentally different kind of computer chip—one that uses light to perform key calculations. ‘Either we invent new kinds of computers to continue,’ says Lightmatter CEO Nick Harris, ‘or AI slows down.’i”

BIOTECH
With This CAD for Genomes, You Can Design New Organisms
Eliza Strickland | IEEE Spectrum
“Imagine being able to design a new organism as easily as you can design a new integrated circuit. That’s the ultimate vision behind the computer-aided design (CAD) program being developed by the GP-write consortium. ‘We’re taking the same things we’d do for design automation in electronics, and applying them to biology,’ says Doug Densmore, an associate professor of electrical and computer engineering at Boston University.”

BIOLOGY
Hey, So These Sea Slugs Decapitate Themselves and Grow New Bodies
Matt Simon | Wired
“That’s right: It pulled a Deadpool. Just a few hours after its self-decapitation, the head began dragging itself around to feed. After a day, the neck wound had closed. After a week, it started to regenerate a heart. In less than a month, the whole body had grown back, and the disembodied slug was embodied once more.”

INTERNET
Move Over, Deep Nostalgia, This AI App Can Make Kim Jong-un Sing ‘I Will Survive’
Helen Sullivan | The Guardian
“If you’ve ever wanted to know what it might be like to see Kim Jong-un let loose at karaoke, your wish has been granted, thanks to an app that lets users turn photographs of anyone—or anything remotely resembling a face—into uncanny AI-powered videos of them lip syncing famous songs.”

ENERGY
GM Unveils Plans for Lithium-Metal Batteries That Could Boost EV Range
Steve Dent | Engadget
“GM has released more details about its next-generation Ultium batteries, including plans for lithium-metal (Li-metal) technology to boost performance and energy density. The automaker announced that it has signed an agreement to work with SolidEnergy Systems (SES), an MIT spinoff developing prototype Li-metal batteries with nearly double the capacity of current lithium-ion cells.”

TECHNOLOGY
Xi’s Gambit: China Plans for a World Without American Technology
Paul Mozur and Steven Lee Myers | The New York Times
“China is freeing up tens of billions of dollars for its tech industry to borrow. It is cataloging the sectors where the United States or others could cut off access to crucial technologies. And when its leaders released their most important economic plans last week, they laid out their ambitions to become an innovation superpower beholden to none.”

SCIENCE
Imaginary Numbers May Be Essential for Describing Reality
Charlie Wood | Wired
“…physicists may have just shown for the first time that imaginary numbers are, in a sense, real. A group of quantum theorists designed an experiment whose outcome depends on whether nature has an imaginary side. Provided that quantum mechanics is correct—an assumption few would quibble with—the team’s argument essentially guarantees that complex numbers are an unavoidable part of our description of the physical universe.”

PHILOSOPHY
What Is Life? Its Vast Diversity Defies Easy Definition
Carl Zimmer | Quanta
“i‘It is commonly said,’ the scientists Frances Westall and André Brack wrote in 2018, ‘that there are as many definitions of life as there are people trying to define it.’ …As an observer of science and of scientists, I find this behavior strange. It is as if astronomers kept coming up with new ways to define stars. …With scientists adrift in an ocean of definitions, philosophers rowed out to offer lifelines.”

Image Credit: Kir Simakov / Unsplash Continue reading

Posted in Human Robots

#438809 This Week’s Awesome Tech Stories From ...

ARTIFICIAL INTELLIGENCE
Facebook’s New AI Teaches Itself to See With Less Human Help
Will Knight | Wired
“Peer inside an AI algorithm and you’ll find something constructed using data that was curated and labeled by an army of human workers. Now, Facebook has shown how some AI algorithms can learn to do useful work with far less human help. The company built an algorithm that learned to recognize objects in images with little help from labels.”

CULTURE
New AI ‘Deep Nostalgia’ Brings Old Photos, Including Very Old Ones, to Life
Kim Lyons | The Verge
“The Deep Nostalgia service, offered by online genealogy company MyHeritage, uses AI licensed from D-ID to create the effect that a still photo is moving. It’s kinda like the iOS Live Photos feature, which adds a few seconds of video to help smartphone photographers find the best shot. But Deep Nostalgia can take photos from any camera and bring them to ‘life.’i”

COMPUTING
Could ‘Topological Materials’ Be a New Medium For Ultra-Fast Electronics?
Charles Q. Choi | IEEE Spectrum
“Potential future transistors that can exceed Moore’s law may rely on exotic materials called ‘topological matter’ in which electricity flows across surfaces only, with virtually no dissipation of energy. And now new findings suggest these special topological materials might one day find use in high-speed, low-power electronics and in quantum computers.”

ENERGY
A Chinese Province Could Ban Bitcoin Mining to Cut Down Energy Use
Dharna Noor | Gizmodo
“Since energy prices in Inner Mongolia are particularly low, many bitcoin miners have set up shop there specifically. The region is the third-largest mining site in China. Because the grid is heavily coal-powered, however, that’s led to skyrocketing emissions, putting it in conflict with President Xi Jinping’s promise last September to have China reach peak carbon emissions by 2030 at the latest and achieve carbon neutrality before 2060.”

VIRTUAL REALITY
Mesh Is Microsoft’s Vision for Sending Your Hologram Back to the Office
Sam Rutherford | Gizmodo
“With Mesh, Microsoft is hoping to create a virtual environment capable of sharing data, 3D models, avatars, and more—basically, the company wants to upgrade the traditional remote-working experience with the power of AR and VR. In the future, Microsoft is planning for something it’s calling ‘holoportation,’ which will allow Mesh devices to create photorealistic digital avatars of your body that can appear in virtual spaces anywhere in the world—assuming you’ve been invited, of course.”

SPACE
Rocket Lab Could Be SpaceX’s Biggest Rival
Neel V. Patel | MIT Technology Review
“At 40 meters tall and able to carry 20 times the weight that Electron can, [the new] Neutron [rocket] is being touted by Rocket Lab as its entry into markets for large satellite and mega-constellation launches, as well as future robotics missions to the moon and Mars. Even more tantalizing, Rocket Lab says Neutron will be designed for human spaceflight as well.”

SCIENCE
Can Alien Smog Lead Us to Extraterrestrial Civilizations?
Meghan Herbst | Wired
“Kopparapu is at the forefront of an emerging field in astronomy that is aiming to identify technosignatures, or technological markers we can search for in the cosmos. No longer conceptually limited to radio signals, astronomers are looking for ways we could identify planets or other spacefaring objects by looking for things like atmospheric gases, lasers, and even hypothetical sun-encircling structures called Dyson spheres.”

DIGITAL CURRENCIES
China Charges Ahead With a National Digital Currency
Nathaniel Popper and Cao Li | The New York Times
“China has charged ahead with a bold effort to remake the way that government-backed money works, rolling out its own digital currency with different qualities than cash or digital deposits. The country’s central bank, which began testing eCNY last year in four cities, recently expanded those trials to bigger cities such as Beijing and Shanghai, according to government presentations.”

Image Credit: Leon Seibert / Unsplash Continue reading

Posted in Human Robots

#437929 These Were Our Favorite Tech Stories ...

This time last year we were commemorating the end of a decade and looking ahead to the next one. Enter the year that felt like a decade all by itself: 2020. News written in January, the before-times, feels hopelessly out of touch with all that came after. Stories published in the early days of the pandemic are, for the most part, similarly naive.

The year’s news cycle was swift and brutal, ping-ponging from pandemic to extreme social and political tension, whipsawing economies, and natural disasters. Hope. Despair. Loneliness. Grief. Grit. More hope. Another lockdown. It’s been a hell of a year.

Though 2020 was dominated by big, hairy societal change, science and technology took significant steps forward. Researchers singularly focused on the pandemic and collaborated on solutions to a degree never before seen. New technologies converged to deliver vaccines in record time. The dark side of tech, from biased algorithms to the threat of omnipresent surveillance and corporate control of artificial intelligence, continued to rear its head.

Meanwhile, AI showed uncanny command of language, joined Reddit threads, and made inroads into some of science’s grandest challenges. Mars rockets flew for the first time, and a private company delivered astronauts to the International Space Station. Deprived of night life, concerts, and festivals, millions traveled to virtual worlds instead. Anonymous jet packs flew over LA. Mysterious monoliths appeared and disappeared worldwide.

It was all, you know, very 2020. For this year’s (in-no-way-all-encompassing) list of fascinating stories in tech and science, we tried to select those that weren’t totally dated by the news, but rose above it in some way. So, without further ado: This year’s picks.

How Science Beat the Virus
Ed Yong | The Atlantic
“Much like famous initiatives such as the Manhattan Project and the Apollo program, epidemics focus the energies of large groups of scientists. …But ‘nothing in history was even close to the level of pivoting that’s happening right now,’ Madhukar Pai of McGill University told me. … No other disease has been scrutinized so intensely, by so much combined intellect, in so brief a time.”

‘It Will Change Everything’: DeepMind’s AI Makes Gigantic Leap in Solving Protein Structures
Ewen Callaway | Nature
“In some cases, AlphaFold’s structure predictions were indistinguishable from those determined using ‘gold standard’ experimental methods such as X-ray crystallography and, in recent years, cryo-electron microscopy (cryo-EM). AlphaFold might not obviate the need for these laborious and expensive methods—yet—say scientists, but the AI will make it possible to study living things in new ways.”

OpenAI’s Latest Breakthrough Is Astonishingly Powerful, But Still Fighting Its Flaws
James Vincent | The Verge
“What makes GPT-3 amazing, they say, is not that it can tell you that the capital of Paraguay is Asunción (it is) or that 466 times 23.5 is 10,987 (it’s not), but that it’s capable of answering both questions and many more beside simply because it was trained on more data for longer than other programs. If there’s one thing we know that the world is creating more and more of, it’s data and computing power, which means GPT-3’s descendants are only going to get more clever.”

Artificial General Intelligence: Are We Close, and Does It Even Make Sense to Try?
Will Douglas Heaven | MIT Technology Review
“A machine that could think like a person has been the guiding vision of AI research since the earliest days—and remains its most divisive idea. …So why is AGI controversial? Why does it matter? And is it a reckless, misleading dream—or the ultimate goal?”

The Dark Side of Big Tech’s Funding for AI Research
Tom Simonite | Wired
“Timnit Gebru’s exit from Google is a powerful reminder of how thoroughly companies dominate the field, with the biggest computers and the most resources. …[Meredith] Whittaker of AI Now says properly probing the societal effects of AI is fundamentally incompatible with corporate labs. ‘That kind of research that looks at the power and politics of AI is and must be inherently adversarial to the firms that are profiting from this technology.’i”

We’re Not Prepared for the End of Moore’s Law
David Rotman | MIT Technology Review
“Quantum computing, carbon nanotube transistors, even spintronics, are enticing possibilities—but none are obvious replacements for the promise that Gordon Moore first saw in a simple integrated circuit. We need the research investments now to find out, though. Because one prediction is pretty much certain to come true: we’re always going to want more computing power.”

Inside the Race to Build the Best Quantum Computer on Earth
Gideon Lichfield | MIT Technology Review
“Regardless of whether you agree with Google’s position [on ‘quantum supremacy’] or IBM’s, the next goal is clear, Oliver says: to build a quantum computer that can do something useful. …The trouble is that it’s nearly impossible to predict what the first useful task will be, or how big a computer will be needed to perform it.”

The Secretive Company That Might End Privacy as We Know It
Kashmir Hill | The New York Times
“Searching someone by face could become as easy as Googling a name. Strangers would be able to listen in on sensitive conversations, take photos of the participants and know personal secrets. Someone walking down the street would be immediately identifiable—and his or her home address would be only a few clicks away. It would herald the end of public anonymity.”

Wrongfully Accused by an Algorithm
Kashmir Hill | The New York Times
“Mr. Williams knew that he had not committed the crime in question. What he could not have known, as he sat in the interrogation room, is that his case may be the first known account of an American being wrongfully arrested based on a flawed match from a facial recognition algorithm, according to experts on technology and the law.”

Predictive Policing Algorithms Are Racist. They Need to Be Dismantled.
Will Douglas Heaven | MIT Technology Review
“A number of studies have shown that these tools perpetuate systemic racism, and yet we still know very little about how they work, who is using them, and for what purpose. All of this needs to change before a proper reckoning can take pace. Luckily, the tide may be turning.”

The Panopticon Is Already Here
Ross Andersen | The Atlantic
“Artificial intelligence has applications in nearly every human domain, from the instant translation of spoken language to early viral-outbreak detection. But Xi [Jinping] also wants to use AI’s awesome analytical powers to push China to the cutting edge of surveillance. He wants to build an all-seeing digital system of social control, patrolled by precog algorithms that identify potential dissenters in real time.”

The Case For Cities That Aren’t Dystopian Surveillance States
Cory Doctorow | The Guardian
“Imagine a human-centered smart city that knows everything it can about things. It knows how many seats are free on every bus, it knows how busy every road is, it knows where there are short-hire bikes available and where there are potholes. …What it doesn’t know is anything about individuals in the city.”

The Modern World Has Finally Become Too Complex for Any of Us to Understand
Tim Maughan | OneZero
“One of the dominant themes of the last few years is that nothing makes sense. …I am here to tell you that the reason so much of the world seems incomprehensible is that it is incomprehensible. From social media to the global economy to supply chains, our lives rest precariously on systems that have become so complex, and we have yielded so much of it to technologies and autonomous actors that no one totally comprehends it all.”

The Conscience of Silicon Valley
Zach Baron | GQ
“What I really hoped to do, I said, was to talk about the future and how to live in it. This year feels like a crossroads; I do not need to explain what I mean by this. …I want to destroy my computer, through which I now work and ‘have drinks’ and stare at blurry simulations of my parents sometimes; I want to kneel down and pray to it like a god. I want someone—I want Jaron Lanier—to tell me where we’re going, and whether it’s going to be okay when we get there. Lanier just nodded. All right, then.”

Yes to Tech Optimism. And Pessimism.
Shira Ovide | The New York Times
“Technology is not something that exists in a bubble; it is a phenomenon that changes how we live or how our world works in ways that help and hurt. That calls for more humility and bridges across the optimism-pessimism divide from people who make technology, those of us who write about it, government officials and the public. We need to think on the bright side. And we need to consider the horribles.”

How Afrofuturism Can Help the World Mend
C. Brandon Ogbunu | Wired
“…[W. E. B. DuBois’] ‘The Comet’ helped lay the foundation for a paradigm known as Afrofuturism. A century later, as a comet carrying disease and social unrest has upended the world, Afrofuturism may be more relevant than ever. Its vision can help guide us out of the rubble, and help us to consider universes of better alternatives.”

Wikipedia Is the Last Best Place on the Internet
Richard Cooke | Wired
“More than an encyclopedia, Wikipedia has become a community, a library, a constitution, an experiment, a political manifesto—the closest thing there is to an online public square. It is one of the few remaining places that retains the faintly utopian glow of the early World Wide Web.”

Can Genetic Engineering Bring Back the American Chestnut?
Gabriel Popkin | The New York Times Magazine
“The geneticists’ research forces conservationists to confront, in a new and sometimes discomfiting way, the prospect that repairing the natural world does not necessarily mean returning to an unblemished Eden. It may instead mean embracing a role that we’ve already assumed: engineers of everything, including nature.”

At the Limits of Thought
David C. Krakauer | Aeon
“A schism is emerging in the scientific enterprise. On the one side is the human mind, the source of every story, theory, and explanation that our species holds dear. On the other stand the machines, whose algorithms possess astonishing predictive power but whose inner workings remain radically opaque to human observers.”

Is the Internet Conscious? If It Were, How Would We Know?
Meghan O’Gieblyn | Wired
“Does the internet behave like a creature with an internal life? Does it manifest the fruits of consciousness? There are certainly moments when it seems to. Google can anticipate what you’re going to type before you fully articulate it to yourself. Facebook ads can intuit that a woman is pregnant before she tells her family and friends. It is easy, in such moments, to conclude that you’re in the presence of another mind—though given the human tendency to anthropomorphize, we should be wary of quick conclusions.”

The Internet Is an Amnesia Machine
Simon Pitt | OneZero
“There was a time when I didn’t know what a Baby Yoda was. Then there was a time I couldn’t go online without reading about Baby Yoda. And now, Baby Yoda is a distant, shrugging memory. Soon there will be a generation of people who missed the whole thing and for whom Baby Yoda is as meaningless as it was for me a year ago.”

Digital Pregnancy Tests Are Almost as Powerful as the Original IBM PC
Tom Warren | The Verge
“Each test, which costs less than $5, includes a processor, RAM, a button cell battery, and a tiny LCD screen to display the result. …Foone speculates that this device is ‘probably faster at number crunching and basic I/O than the CPU used in the original IBM PC.’ IBM’s original PC was based on Intel’s 8088 microprocessor, an 8-bit chip that operated at 5Mhz. The difference here is that this is a pregnancy test you pee on and then throw away.”

The Party Goes on in Massive Online Worlds
Cecilia D’Anastasio | Wired
“We’re more stand-outside types than the types to cast a flashy glamour spell and chat up the nearest cat girl. But, hey, it’s Final Fantasy XIV online, and where my body sat in New York, the epicenter of America’s Covid-19 outbreak, there certainly weren’t any parties.”

The Facebook Groups Where People Pretend the Pandemic Isn’t Happening
Kaitlyn Tiffany | The Atlantic
“Losing track of a friend in a packed bar or screaming to be heard over a live band is not something that’s happening much in the real world at the moment, but it happens all the time in the 2,100-person Facebook group ‘a group where we all pretend we’re in the same venue.’ So does losing shoes and Juul pods, and shouting matches over which bands are the saddest, and therefore the greatest.”

Did You Fly a Jetpack Over Los Angeles This Weekend? Because the FBI Is Looking for You
Tom McKay | Gizmodo
“Did you fly a jetpack over Los Angeles at approximately 3,000 feet on Sunday? Some kind of tiny helicopter? Maybe a lawn chair with balloons tied to it? If the answer to any of the above questions is ‘yes,’ you should probably lay low for a while (by which I mean cool it on the single-occupant flying machine). That’s because passing airline pilots spotted you, and now it’s this whole thing with the FBI and the Federal Aviation Administration, both of which are investigating.”

Image Credit: Thomas Kinto / Unsplash Continue reading

Posted in Human Robots

#437820 In-Shoe Sensors and Mobile Robots Keep ...

In shoe sensor

Researchers at Stevens Institute of Technology are leveraging some of the newest mechanical and robotic technologies to help some of our oldest populations stay healthy, active, and independent.

Yi Guo, professor of electrical and computer engineering and director of the Robotics and Automation Laboratory, and Damiano Zanotto, assistant professor of mechanical engineering, and director of the Wearable Robotic Systems Laboratory, are collaborating with Ashley Lytle, assistant professor in Stevens’ College of Arts and Letters, and Ashwini K. Rao of Columbia University Medical Center, to combine an assistive mobile robot companion with wearable in-shoe sensors in a system designed to help elderly individuals maintain the balance and motion they need to thrive.

“Balance and motion can be significant issues for this population, and if elderly people fall and experience an injury, they are less likely to stay fit and exercise,” Guo said. “As a consequence, their level of fitness and performance decreases. Our mobile robot companion can help decrease the chances of falling and contribute to a healthy lifestyle by keeping their walking function at a good level.”

The mobile robots are designed to lead walking sessions and using the in-shoe sensors, monitor the user’s gait, indicate issues, and adjust the exercise speed and pace. The initiative is part of a four-year National Science Foundation research project.

“For the first time, we’re integrating our wearable sensing technology with an autonomous mobile robot,” said Zanotto, who worked with elderly people at Columbia University Medical Center for three years before coming to Stevens in 2016. “It’s exciting to be combining these different areas of expertise to leverage the strong points of wearable sensing technology, such as accurately capturing human movement, with the advantages of mobile robotics, such as much larger computational powers.”

The team is developing algorithms that fuse real-time data from smart, unobtrusive, in-shoe sensors and advanced on-board sensors to inform the robot’s navigation protocols and control the way the robot interacts with elderly individuals. It’s a promising way to assist seniors in safely doing walking exercises and maintaining their quality of life.

Bringing the benefits of the lab to life

Guo and Zanotto are working with Lytle, an expert in social and health psychology, to implement a social connectivity capability and make the bi-directional interaction between human and robot even more intuitive, engaging, and meaningful for seniors.

“Especially during COVID, it’s important for elderly people living on their own to connect socially with family and friends,” Zanotto said, “and the robot companion will also offer teleconferencing tools to provide that interaction in an intuitive and transparent way.”

“We want to use the robot for social connectedness, perhaps integrating it with a conversation agent such as Alexa,” Guo added. “The goal is to make it a companion robot that can sense, for example, that you are cooking, or you’re in the living room, and help with things you would do there.”

It’s a powerful example of how abstract concepts can have meaningful real-life benefits.

“As engineers, we tend to work in the lab, trying to optimize our algorithms and devices and technologies,” Zanotto noted, “but at the end of the day, what we do has limited value unless it has impact on real life. It’s fascinating to see how the devices and technologies we’re developing in the lab can be applied to make a difference for real people.”

Maintaining balance in a global pandemic

Although COVID-19 has delayed the planned testing at a senior center in New York City, it has not stopped the team’s progress.

“Although we can’t test on elderly populations yet, our students are still testing in the lab,” Guo said. “This summer and fall, for the first time, the students validated the system’s real-time ability to monitor and assess the dynamic margin of stability during walking—in other words, to evaluate whether the person following the robot is walking normally or has a risk of falling. They’re also designing parameters for the robot to give early warnings and feedback that help the human subjects correct posture and gait issues while walking.”

Those warnings would be literally underfoot, as the in-shoe sensors would pulse like a vibrating cell phone to deliver immediate directional information to the subject.

“We’re not the first to use this vibrotactile stimuli technology, but this application is new,” Zanotto said.

So far, the team has published papers in top robotics publication venues including IEEE Transactions on Neural Systems and Rehabilitation Engineering and the 2020 IEEE International Conference on Robotics and Automation (ICRA). It’s a big step toward realizing the synergies of bringing the technical expertise of engineers to bear on the clinical focus on biometrics—and the real lives of seniors everywhere. Continue reading

Posted in Human Robots

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots